Related Experiment Video
Updated: Jan 24, 2026
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
Published on: February 17, 2023
Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates
Anna K Renfrew1, Johannes Karges2, Rosario Scopelliti1
1Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015, Lausanne, Switzerland.
Abstract:
Cancer is currently one of the deadliest diseases worldwide. Based on the high incidence of this disease, the side effects associated with current chemotherapies and the appearance of drug resistance, considerable efforts have been directed towards the development of new anticancer drugs with new modes of action. Metal-based compounds are particularly attractive candidates due to their metabolic mechanisms, which differ substantially from those of organic drugs. Of special interest in this context are organometallic ruthenium(II) complexes of the type [Ru(η6 -arene)(pta)Cl2 ] (arene: p-cymene, toluene, benzene, etc.; pta: 1,3,5-triaza-7-phosphaadamantane), which are abbreviated to RAPTA. Complementary to chemotherapy, photoactivated chemotherapy is a technique that has received increasing attention towards the development of treatment for numerous kinds of cancer. With this in mind, a photoactive RAPTA-type complex bearing azide ligands has been designed. The diazide complex, [Ru(η6 -p-cymene)pta-(N3 )2 ], is inert in water, but slowly releases the azide ligand upon exposure to light. Consequently, the in vitro cytotoxicity of the complex in the dark and upon light exposure at λ=450 nm in human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE-1) cells was investigated. Although the cytotoxicity of the complex was found to be modest in the dark, an increase in toxicity upon light exposure was observed.
Insights
New ruthenium(II) anticancer drugs, known as RAPTA complexes, show increased cancer cell toxicity when activated by light. This photoactivated chemotherapy approach offers a promising alternative to traditional cancer treatments.
Area of Science:
- Medicinal Chemistry
- Organometallic Chemistry
- Cancer Research
Background:
- Cancer remains a leading global cause of death, necessitating novel therapeutic strategies beyond conventional chemotherapy due to side effects and drug resistance.
- Metal-based compounds, particularly organometallic ruthenium(II) complexes (RAPTA), offer unique metabolic pathways distinct from organic drugs, making them attractive anticancer drug candidates.
- Photoactivated chemotherapy (PACT) is an emerging strategy that utilizes light to activate therapeutic agents, enhancing targeted cancer treatment.
Purpose of the Study:
- To design and synthesize a photoactive ruthenium(II) complex of the RAPTA type incorporating azide ligands for potential use in photoactivated chemotherapy.
- To investigate the in vitro cytotoxicity of the novel diazide ruthenium complex in cancer cells (HeLa) and noncancerous cells (RPE-1) under dark and light conditions.
Main Methods:
- Synthesis of a novel diazide ruthenium(II) complex: [Ru(η⁶-p-cymene)pta-(N₃)₂].
- Assessment of the complex's stability and light-induced ligand release in aqueous media.
- In vitro cytotoxicity assays on human cervical carcinoma (HeLa) and noncancerous retinal pigment epithelium (RPE-1) cells, comparing dark conditions with light exposure (λ=450 nm).
Main Results:
- The synthesized diazide ruthenium complex, [Ru(η⁶-p-cymene)pta-(N₃)₂], demonstrated inertness in water but released azide ligands upon light exposure.
- The complex exhibited modest cytotoxicity in the dark against HeLa cells.
- Significant enhancement of cytotoxicity was observed upon light activation (λ=450 nm) in HeLa cells, with minimal impact on RPE-1 cells.
Conclusions:
- The photoactive ruthenium(II) RAPTA-type complex with azide ligands shows potential as a photoactivated chemotherapeutic agent.
- Light activation significantly increases the anticancer efficacy of the complex, suggesting a targeted therapeutic approach with reduced systemic toxicity.
- This study highlights the promise of developing light-responsive metal-based drugs for improved cancer treatment strategies.
More Related Videos
Related Concept Videos
01:30Prodrugs
Prodrugs help overcome...
02:16Light Acquisition
01:35Light as Energy
Photons
A photon is a discrete electromagnetic particle or bundle of energy. Photons are characterized by their frequency, wavelength, and amplitude, similar to the properties of a wave. Waves with higher frequencies transmit more energy and have shorter wavelengths than longer wavelengths that transmit...
02:00Photoreceptors and Plant Responses to Light
02:12The Wave Nature of Light
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...